Omri Amirav-Drory, Ph.D. is GP at NFX Bio. He is a scientist and an operator who has founded, scaled, and invested in some of today’s most important new tech bio companies. He founded Genome Compiler, which developed software for genetic engineers and molecular and synthetic biologists, and led it to a successful acquisition by Twist Bioscience. He went on to lead Corporate Development at Twist, a next-generation DNA synthesis company currently valued at approximately $10 Billion. Omri was also the founding partner at Tech.Bio where he invested and advised in companies like Mammoth Biosciences, immunai, C2i Genomics, and more. He is a graduate of Tel Aviv University where he received a B.S. in Biochemistry and Molecular Biology and a Ph.D. in Biochemistry. He was a Fulbright Postdoctorate in Biochemistry & Molecular Biology at Stanford University school of medicine & HHMI. One of the most connected leaders in the tech biofield, Omri understands what it means to be a Scientist-CEO and is committed to a future where this is the norm, not the exception. If you want to reach Omri for investment, you can email him at [email protected], and it’s best to send him a private link to your Company Brief.